InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-03 | 2026-03-04 | ABALLI JOHN | Director & President and CEO | Sale | 15.7K | $3.62 | $57K | 687.3K | View ↗ | |
| 2026-02-24 | 2026-02-25 | ABALLI JOHN | Director & President and CEO | Sale | 11.4K | $3.61 | $41K | 703.0K | View ↗ | |
| 2026-02-24 | 2026-02-25 | Black Jeffrey G. | Chief Financial Officer | Sale | 1,584 | $3.61 | $6K | 267.4K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $66.6M+19.7% | $55.6M+5.9% | $52.5M+15.3% | $45.6M |
| Cost of revenue | $27.8M+23.3% | $22.5M-2.4% | $23.1M-4.6% | $24.2M |
| Gross profit | $38.8M+17.2% | $33.1M+12.4% | $29.5M | — |
| Selling, general and administrative expenses | $46.6M+12.7% | $41.4M-12.8% | $47.4M-8.8% | $52.0M |
| Research and development expenses | $6.3M+16.4% | $5.4M+10.5% | $4.9M-50.7% | $9.9M |
| Total operating expenses | $52.9M+13.1% | $46.7M-10.6% | $52.3M-42.9% | $91.6M |
| Loss from operations | -$14.1M-3.2% | -$13.6M+40.3% | -$22.8M+50.4% | -$46.1M |
| Interest expense | -$4.3M-93.3% | -$2.2M+4.3% | -$2.3M+4.6% | -$2.4M |
| Loss on extinguishment of debt | -$295K | $0 | — | — |
| Change in fair value of warrant liability | -$1.5M | $0 | — | — |
| Interest income | $289K-62.3% | $767K-49.4% | $1.5M+82.7% | $830K |
| Loss before income taxes | -$19.9M-31.8% | -$15.1M+36.2% | -$23.7M+50.4% | -$47.7M |
| Income tax expense | -$51K-325.0% | -$12K+63.6% | -$33K-111.7% | $282K |
| Net loss | -$20.0M-32.0% | -$15.1M+36.2% | -$23.7M+50.0% | -$47.4M |
| Net loss per share, basic (in dollars per share) | -$930-12.0% | -$830+38.1% | -$1K+51.6% | -$3K |
| Net loss per share, diluted (in dollars per share) | -$930-12.0% | -$830+38.1% | -$1K+51.6% | -$3K |
| Weighted-average number of shares used to compute net loss per share, basic (in shares) | $21.56B+18.4% | $18.20B+3.0% | $17.68B+3.5% | $17.08B |
| Weighted-average number of shares used to compute net loss per share, diluted (in shares) | $21.56B+18.4% | $18.20B+3.0% | $17.68B+3.5% | $17.08B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%
The Exagen Inc. (NASDAQ:XGN) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Exagen (XGN) Q1 2026 Earnings Transcript
Exagen Inc. Q1 2026 Earnings Call Summary